June 15 (Reuters) - A former portfolio manager conducted
insider trading ahead of federal regulatory announcements tied
to the healthcare industry, and fraudulently inflated the value
of securities he oversaw, a U.S. regulator said on Wednesday.
Read more
No comments:
Post a Comment